Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing
By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports
The maturation of the outsourcing industry comes with various benefits, a notable one being the removal of the multimillion- dollar financial barrier of in-house manufacturing for new and emerging companies. Virtual biopharmas are able to use CDMOs to further their discoveries through access to state-of-the-art manufacturing facilities, regulatory knowledge, and scientific expertise not possessed in-house. The proliferation of startup biopharmas over the past couple of decades will certainly speed up the pace of new medicines coming to market and hopefully improve and extend the lives of patients in the process.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.